“Thanks to the strong contributions from our team, we delivered differentiated performance in 2023 and enabled our customers’ success,” s...
Carcinotech has raised $5.3 million of funding as the company looks to build on its traction in the UK and Europe, with US expansion planned later this yea...
Novartis, under the leadership of CEO Vas Narasimhan, has announced robust financial results for the full year of 2023. The company reported a 10% growth i...
Robust sales of CHF 6.7 billion, delivering 10.9%1 CER sales growth CORE EBITDA of CHF 2 billion, resulting in a margin of 29.8% Continued growth inves...
The round also included premier investors such as WI Harper Group, a leading cross-border venture capital firm, and SEEDS Capital, the investment arm of go...
Fourth-quarter reported sales increased 1.5 percent; organic sales growth for the underlying base business increased 11.0 percent Full-year 2023 reporte...
New investment from DRW Venture Capital LLC and Tolmar International Ltd Funds will be used to advance its proprietary, silica-based, drug delivery...
Pfizer does not endorse TRC Capital Investment’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares in respons...
Unlocking the next generation of life sciences innovations will depend on researchers' abilities to not just uncover new data, but to identify patterns at ...
QIAGEN announced a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase tha...
Inaugural strategy is one of the largest ever first-time private life sciences growth funds Fundraise closed above its original target, reflecting stron...
"Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this sp...
This investment opportunity offers a unique chance for individuals and institutions to actively participate in the growth and transformation of the healthc...
The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.&nb...
© 2025 Biopharma Boardroom. All Rights Reserved.
